Dr. Cooke joined NovaDigm Therapeutics as Chief Executive Officer in 2009. He has broad leadership experience in both emerging and large multinational companies in the fields of vaccines and immunotherapeutics. Dr. Cooke joined Merck when it launched a dedicated vaccine business unit in 1991 and was also a founding member of Sanofi Pasteur-MSD, a European joint venture between Sanofi Pasteur and Merck. Dr. Cooke was the Chief Executive Officer of Mojave Therapeutics, a company developing therapeutic vaccines against viral infections and cancer, which was sold to Antigenics in 2004. He was then Chief Operating Officer of AVANT Immunotherapeutics prior to its acquisition by CellDex Therapeutics in 2008.
Dr. Cooke is a member of the National Vaccine Advisory Committee of the U.S. Department of Health and Human Services, where he represents the biotechnology industry. He is a member and previous Co-Chair of the Biotechnology Innovation Organization’s Vaccine Policy Advisory Committee and a member of BIO’s Antimicrobial Resistance Working Group. He represented the vaccine industry on the Global Alliance for Vaccines and Immunization (GAVI) Working Group when it was launched in 2000. Dr. Cooke has a bachelor’s degree from Saint Joseph’s University, and a Ph.D. in bio-organic chemistry and an M.B.A. from Columbia University.